FUJIFILM Irvine Scientific’s new manufacturing facility in Tilburg, the Netherlands, is now fully operational.
FUJIFILM Irvine Scientific’s new manufacturing facility in Tilburg, the Netherlands is now open and fully operational, the company announced on Dec. 8, 2021. The new facility provides life science manufacturing and, with the company’s other manufacturing locations in the United States and Japan, increases production capacity of cell culture media products. The Tilburg site acts as a hub for both European and global markets.
The Tilburg site is the third manufacturing facility in FUJIFILM Irvine Scientific’s roster and represents an important step in the company’s long-term plans to secure its production capacity to meet growing market demand. The facility’s location in central Europe makes it a source of local supply, increasing supply chain efficiency and enabling cost-savings in shipping.
The facility was built on sustainable initiatives following the parent company’s Fujifilm Sustainability Value Plan 2030. Strategies in use at the new facility include working towards a carbon dioxide-neutral status, using wind energy for production process, and using sustainable technologies. such as membrane bioreactors, for wastewater purification.
The Tilburg facility uses approximately 13,500 m2 of space and manufactures dry powder media, liquid media, buffers, and water for injection. The facility initially increases the company’s production capacity with approximately 320,000 kg/year of dry powder media and greater than 470,000 L/year of liquids. The company can also expand rapidly if the necessity arises.
“We worked steadily to achieve milestones for construction, validation, and commissioning of this manufacturing facility,” said Yutaka Yamaguchi, chairman and CEO, FUJIFILM Irvine Scientific, in a company press release. “Even with the global challenges faced in recent years, FUJIFILM Irvine Scientific was determined to provide customers in Europe with local service that strengthens the supply chain and increases manufacturing capacity. It is extremely rewarding to see this commitment realized.”
Source: FUJIFILM Irvine Scientific
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.